Laurie McGinley, Washington Post

Laurie McGinley

Washington Post

Washington, DC, United States

Contact Laurie

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • Unknown
Past:
  • Washington Post
  • ScienceAlert

Past articles by Laurie:

FDA gives full approval to first drug to clearly, but modestly, slow Alzheimer’s

The medicine, called Leqembi, slowed decline by 27 percent over 18 months compared with placebo, a study showed. But side effects and cost are fueling controversy. → Read More

For Alzheimer’s patients, a new era of treatment brings hope and risk

A drug called Leqembi, which modestly slows progression of the disease, is expected soon to receive full approval from federal regulators. → Read More

Alzheimer’s drug Leqembi backed by FDA advisers for full approval

Controversies surrounding the drug — involving safety concerns, the drug’s modest efficacy and its high cost — continue to swirl. → Read More

Lilly to seek FDA approval for Alzheimer’s drug that firm says slows decline

The drug, donanemab, is the latest treatment to target amyloid beta, a protein that builds up in the brain and is a signature characteristic of Alzheimer’s. → Read More

The new face of Alzheimer’s: Early-stage patients who refuse to surrender

For years, doctors and patients thought there was little to do when dementia was diagnosed, even at an early stage. Now, potentially sweeping changes loom. → Read More

FDA proposes switching to annual coronavirus vaccine, mimicking flu model

The proposed change is designed to reduce the complexity of the vaccine regimen for the public, doctors and manufacturers. → Read More

FDA declines to give accelerated approval to Eli Lilly’s Alzheimer’s drug, firm says

The Food and Drug Administration said it needed safety data on more patients, the company said. → Read More

Alzheimer’s drug that slows cognitive decline gets FDA approval

The drug, lecanemab, removes a sticky protein from the brain called amyloid beta, which is thought to play a key role in the memory-robbing illness. → Read More

Is it Alzheimer’s? Families want to know, and blood tests may offer answers.

For the first time, simple blood tests are emerging as potentially crucial tools to help physicians pinpoint Alzheimer's. → Read More

Experimental Alzheimer’s drug from Roche fails in trials

It is a discouraging development that underscores the challenges of developing treatments for the memory-robbing disease. → Read More

FDA authorizes Novavax coronavirus booster shot

Adults can receive the Novavax booster six months after completing their primary series of any coronavirus vaccine, including Moderna and Pfizer shots. → Read More

What to know about the new ALS drug

The drug, Relyvrio, is only the third ALS treatment cleared by the Food and Drug Administration in almost three decades. → Read More

FDA approves first ALS drug in 5 years after pleas from patients

The newly approved therapy, called AMX0035, is designed to slow the disease by protecting nerve cells in the brain and spinal cord destroyed by ALS. → Read More

Experimental Alzheimer’s drug slows cognitive decline in trial, firms say

Makers of the drug have already applied to the Food and Drug Administration for accelerated approval for lecanemab, based on earlier-stage data. → Read More

FDA advisers recommend approval of controversial ALS drug

The vote increases the likelihood that the Food and Drug Administration will clear the first drug for the disease in five years. → Read More

Desperate patients want a new ALS drug. The FDA is not sure it works.

The therapy is the latest to raise questions about how the FDA assesses drugs for devastating diseases, such as ALS and Alzheimer's. → Read More

Coronavirus boosters targeting omicron get FDA blessing for fall push

The shots are expected to be available right after Labor Day. → Read More

For sleep apnea patients with recalled CPAP machines, restless nights

Millions of machines used to treat the sleep condition have been recalled. → Read More

Amid controversies, FDA seeks advice on food and tobacco operations

Food and Drug Administration Commissioner Robert M. Califf said in a statement that “the agency has confronted a series of challenges." → Read More

Drugmaker seeks approval for first nonprescription birth control pill in U.S.

The request hands regulators a major reproductive health issue weeks after the Supreme Court decision striking down the constitutional right to abortion. → Read More